Say Hello!
Don’t be shy.

 
0333 323 1843
 

[email protected]

 

BioCity Group HQ:
Pennyfoot Street
Nottingham
NG1 1GF

BioCity-based businesses top the rankings of Pharma Times Pharma Fast 50

Pharma Fast 50

BioCity-based businesses top the rankings of Pharma Times Pharma Fast 50

Home > Blogs > BioCity-based businesses top the rankings of Pharma Times Pharma Fast 50

Read time: 2 minutes

Mar 6, 2020

Pharma Fast 50

PharmaTimes has presented Alantra’s annual ranking of the fastest growing private pharma companies in the UK. The ranking, based on companies’ revenue growth over the past two years, provides a snapshot of the innovative, entrepreneurial and fleet-of-foot British businesses that are driving the sector forward.

 

The continued rise of the CRO and, particularly, the preclinical CRO was clear to see with many reaching the top places on the overall list, notably, three BioCity-based businesses, BioAscent, Charnwood Molecular and Sygnature Discovery.

 

 

 

Excerpt from Alantra Pharma Fast 50, by Tom Cowap. Read the article in full here > PharmaTimes The Pharma Fast 50

 

“Enter the UK’s preclinical CRO sector. While outsourcers might once have been tempted to use ostensibly cheaper partners in markets such as India and China, this trend has been reversing, says Charnwood’s chief executive Steve Allin. “The UK’s CRO market felt very vulnerable ten years ago, but work has now started to come back from Asia,” he says. “Partly that; s because the price differential has decreased, but it’s also about quality of output: value is more important that price and a cheaper arrangement does not offer that if you’re not getting the results you need.”

 

Dr Richard Weaver, chief executive of XenoGesis, a preclinical DMPK CRO with outstanding rates of growth and one of our emerging contenders, says that outsourcers are now more adaptable and imaginative. “I always ask whether you’re outsourcing creativity or capacity – if it’s the former, it’s us you want,” he says. “Biotechs are looking for teams of specialists who do more than just what they’re told; they also help avoid dead ends and increase speed to market.”

 

In such a flight to quality, the UK is remarkably well-positioned, outcompeting the US on price but offering a wealth of expertise. UK operators have at their disposal facilities and equipment built and maintained, but no longer wanted, by big pharma, as well as a very strong talent pool, not least through constant exchanges with academia. At a more senior level, many of the chemists and biologists who once worked for big pharma have moved into the preclinical space in the UK, unlike in the US where easy access to venture capital finance has persuaded many to launch biotechs of their own.

 

The ground is therefore fertile for smaller specialists providing services in particular niches. “We certainly don’t feel any need to be a one-stop-shop at this stage” adds Charnwood’s Steve Allin. “Instead, we often partner with other businesses we know well who are specialists at what they do and it’s an approach that clients are very happy with.”

 

Paul Smith, chief executive of BioAscent, takes a similar view. “We are a really good fit with the new breed of virtual biotechs which need experts who can work in partnership,” he says. “Your competitive advantage comes down to the quality of your scientists and we believe we will compare favourably to anyone.”

 

Excerpt from Alantra Pharma Fast 50, by Tom Cowap. Read the article in full here > PharmaTimes The Pharma Fast 50

 

BioCity-based businesses named in PharmaTime Pharma Fast 50.

#3 | BioAscent | Based at BioCity Glasgow

#10 | Charnwood Molecular | Based at BioCity Nottingham

#12 | Sygnature Discovery | Based at BioCity Nottingham 

 

TAGS: BioCity, BioCity Glasgow, BioCity company, Blog, CRO's, Company growth, Life Science, Medical Chemistry, Nottingham, Scotland